Skip to content

Evaluation of REMIFENTANIL as an alternative to curare for rapid sequence anesthetic induction in patients at risk of gastric fluid inhalation

Evaluation of REMIFENTANIL as an alternative to curare for rapid sequence anesthetic induction in patients at risk of gastric fluid inhalation - REMICrush

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2019-000753-31-FR
Enrollment
1150
Registered
2019-05-14
Start date
2019-07-04
Completion date
Unknown
Last updated
2021-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anesthetic induction MedDRA version: 20.0 Level: LLT Classification code 10002326 Term: Anesthetic induction System Organ Class: 100000004865

Interventions

Trade Name: REMIFENTANIL Pharmaceutical Form: Powder for solution for injection/infusion Product Name: Suxamethonium 50 mg/ml solution injectable Product Code: PRD7135239 Pharmaceutical Form: Solutio

Sponsors

CHU Nantes
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Female or male. - Aged 18 to 80 years old - Intervention requiring general anesthesia with orotracheal intubation - Anesthetic management with indication of induction in rapid sequence - Risk of gastric fluid inhalation defined by at least one of the following criteria: fasting period =65 years) yes F.1.3.1 Number of subjects for this age range 300

Exclusion criteria

Exclusion criteria: - impossible Intubation planned - Known or suspected history of allergy to curares and/or remifentanil - History of neuromuscular disease contraindicating the use of curares - History of residual curarization - History of malignant hyperthermia - Preoperative respiratory distress (SpO2 < 95% in ambient air) - Preoperative shock (under vasopressor amines) - Patient in cardiorespiratory arrest - A woman of childbearing potential and of childbearing potential who has an ongoing pregnancy and/or clinical signs suggestive of an ongoing pregnancy and/or who does not have a contraceptive or contragestive method and has had unprotected sexual relations within 15 days after the last menstrual period. - Patients under guardianship or curatorship - Intended use of ETOMIDATE for rapid sequence induction

Design outcomes

Primary

MeasureTime frame
Main Objective: The main objective of the study is to demonstrate the non-inferiority of a rapid sequence anesthetic induction without curare with remifentanil on the prevention of major complications related to tracheal intubation compared to a rapid sequence induction with curare of short duration of action.;Timepoint(s) of evaluation of this end point: within 10 minutes of anesthetic induction;Secondary Objective: The secondary objectives are 1) Compare the effectiveness of rapid sequence intubation with or without rapid action curares 2) Compare the tolerance of induction of rapid sequence induction with or without rapid action curares 3) Compare the ability to prevent post-operative respiratory complications ;Primary end point(s): The main criteria is the rate of tracheal intubation without major complications defined by the combination of the following criteria: 1) Tracheal intubation after = 2 laryngoscopies 2) Absence of gastric fluid inhalation through the vocal cords within 10 minutes of anesthetic induction 3) Absence of desaturation defined by SpO2 < 95% within 10 minutes of anesthetic induction. 4) Absence of severe hemodynamic instability defined as hypotension (WFP = 50 mmHg) or hypertension (WFP = 110 mmHg) within 10 minutes of anesthetic induction 5) Absence of a sustained ventricular rhythm disorder (i.e., requiring pharmacological or electrical intervention to reduce or last more than 30 seconds), ventricular fibrillation or cardiac arrest within 10 minutes of anesthetic induction 6) Absence of a Grade III or IV anaphylactic reaction of the 2013 HAS classification within 10 minutes of the anesthetic induction

Secondary

MeasureTime frame
Secondary end point(s): The secondary evaluation criteria are: 1. Intubation quality score (IDS-3 score) 2. The Cormack-Lehane and POGO score values 3. The frequency of patients for whom a technique to assist tracheal intubation was required 4. The time between the administration of the hypnotic (beginning of anesthetic induction) and the achievement of the 6th capnography curve (effective tracheal intubation) 5. The frequency of patients who have had desaturation between 95% and 80% and < 80% of SpO2 within 10 minutes of anesthetic induction. 6. The frequency of patients with severe hemodynamic disorder defined as a heart rate of less than 45 bpm and/or a heart rate of more than 110 bpm and/or a PAS of less than 80 mmHg and/or a PAS of more than 160 mmHg and/or a MAP of less than 55 mmHg and/or a MAP of more than 100 mmHg within 10 minutes of the anaesthetic induction. 7. The frequency of patients with dental or tracheal lesions (endoscopic confirmation for the latter) 8. The frequency of patients who have had a Grade I or II allergic event of the 2013 HAS classification within 10 minutes of the anesthetic induction. 9. Score POST values in SSPI at 1 hour post-extubation (estimation of laryngeal lesions in immediate post-operative care) Translated with www.DeepL.com/Translator;Timepoint(s) of evaluation of this end point: Timepoints of evaluation of these end points are: 1. After intubation 2. After intubation 3. After intubation 4. After intubation 5. within 10 minutes of the anaesthetic induction 6. within 10 minutes of the anaesthetic induction. 7. After intubation 8. within 10 minutes of the anesthetic induction. 9. in immediate post-operative care

Countries

France

Contacts

Public ContactDirection de la Recherche

CHU NANTES

bp-prom-reg@chu-nantes.fr3325348283533

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026